Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Rucaparib in mCRPC
NCT04253262Phase 2Active, not recruiting
- Sponsor
- Brown University
- Start
- Apr 2020
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib, rucaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Brown University. Started Apr 2020; status: active, not recruiting.
02
Drugs
copanlisibrucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04253262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253262.